Benzinga

Benzinga

Benzinga

viernes, agosto 21

Palvella Therapeutics Inc

PVLANASDAQ
Trade with Public
Trade with Public
$142.58
-7.38-4.92%
al cierre: Aug 19, 5:00 PM EST
$142.59
-7.37-4.91%
Premercado: 8:01 AM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Palvella Therapeutics Financials

Palvella Therapeutics (PVLA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Palvella Therapeutics Q2 EPS $(1.52) Misses $(1.14) Estimate

Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.52) per share which missed the analyst consensus estimate of $(1.14) by 33.33 percent. This is a 76.74 percent decrease over losses of $(0.86) per
Benzinga Newsdesk

PRO
Palvella Therapeutics Q1 EPS $(1.20) Misses $(0.93) Estimate

Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.20) per share which missed the analyst consensus estimate of $(0.93) by 29.03 percent. This is a 62.16 percent decrease over losses of $(0.74) per
Benzinga Newsdesk

PRO
Palvella Therapeutics Q4 EPS $(1.08) Misses $(0.91) Estimate

Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.91) by 18.29 percent. This is a 79.89 percent increase over losses of $(5.37) per
Benzinga Newsdesk

Earnings Scheduled For March 31, 2026

Benzinga Insights

Dow Jumps 800 Points; ISM Manufacturing PMI Falls In December

Avi Kapoor

PRO
Palvella Therapeutics Q3 EPS $(1.03) Misses $(0.83) Estimate

Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.03) per share which missed the analyst consensus estimate of $(0.83) by 23.5 percent. This is a 73.86 percent increase over losses of $(3.94) per share
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved